These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 8504018)

  • 1. A risk-benefit assessment of tamoxifen therapy.
    Catherino WH; Jordan VC
    Drug Saf; 1993 May; 8(5):381-97. PubMed ID: 8504018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of tamoxifen in the treatment and prevention of breast cancer.
    Jordan VC
    Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen in postmenopausal women a safety perspective.
    Robinson E; Kimmick GG; Muss HB
    Drugs Aging; 1996 May; 8(5):329-37. PubMed ID: 8935395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
    Esteva FJ; Hortobagyi GN
    Breast; 2006 Jun; 15(3):301-12. PubMed ID: 16230014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should adjuvant tamoxifen therapy be stopped at 5 years?
    Bilimoria MM; Assikis VJ; Jordan VC
    Cancer J Sci Am; 1996; 2(3):140-50. PubMed ID: 9166514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen in axillary node--negative breast cancer: multisystem benefits and risks.
    Love RR
    Cancer Invest; 1992; 10(6):587-93. PubMed ID: 1422894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials.
    Jordan VC
    Prog Clin Biol Res; 1988; 262():105-23. PubMed ID: 3287387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
    Gradishar WJ
    Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term adjuvant tamoxifen therapy for breast cancer.
    Jordan VC
    Breast Cancer Res Treat; 1990 May; 15(3):125-36. PubMed ID: 2196941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer.
    Jordan VC
    Annu Rev Pharmacol Toxicol; 1995; 35():195-211. PubMed ID: 7598491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks and benefits of tamoxifen therapy.
    Assikis VJ; Jordan VC
    Oncology (Williston Park); 1997 Feb; 11(2 Suppl 1):21-3. PubMed ID: 9065923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective estrogen-receptor modulators in 2001.
    O'Regan RM; Gradishar WJ
    Oncology (Williston Park); 2001 Sep; 15(9):1177-85, 1189-90; discussion 1190-4. PubMed ID: 11589065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of tamoxifen in the long-term treatment and prevention of breast cancer.
    Jordan VC
    Oncology (Williston Park); 1988 Sep; 2(9):19-28. PubMed ID: 3079292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of tamoxifen on the endometrium.
    Barakat RR
    Oncology (Williston Park); 1995 Feb; 9(2):129-34; discussion 139-40, 142. PubMed ID: 8771096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.